Nurix Therapeutics Inc (NRIX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.69B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nurix Therapeutics Inc (NRIX) Financials: Revenue, Profit and Cash Flow
Nurix Therapeutics reported revenue of $83.98M for the fiscal year ended Nov 30, 2025, up 54.0% from the year before. That year, net income was -$264.46M with a net margin of -314.9%, operating cash flow was -$249.47M and free cash flow was -$263.47M. The quarter ended Aug 31, 2026 had revenue of $673.06M and net income of $549.81M.
Revenue and Margins
Over the 7 years to Nov 2025, revenue grew from $37.45M, a compound annual rate of 12.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Nov 2025 | $83.98M | +54.0% | 100.0% | -340.2% | -314.9% |
| Nov 2024 | $54.55M | -29.1% | 100.0% | -390.5% | -354.9% |
| Nov 2023 | $76.99M | +99.3% | 100.0% | -201.4% | -187.0% |
| Nov 2022 | $38.63M | +29.8% | 100.0% | -476.0% | -466.9% |
| Nov 2021 | $29.75M | +66.9% | 100.0% | -396.3% | -393.9% |
| Nov 2020 | $17.82M | -42.7% | 100.0% | -364.7% | -242.7% |
| Nov 2019 | $31.11M | -16.9% | 100.0% | -71.5% | -69.7% |
| Nov 2018 | $37.45M | N/A | -8.2% | -26.0% | -25.2% |
Income Statement
In the fiscal year ended Nov 2025, the net loss widened from the year before. In the quarter ended Aug 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 | Nov 2020 | Nov 2019 | Nov 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83.98M | $54.55M | $76.99M | $38.63M | $29.75M | $17.82M | $31.11M | $37.45M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $40.51M |
| Gross profit | $83.98M | $54.55M | $76.99M | $38.63M | $29.75M | $17.82M | $31.11M | -$3.06M |
| Research and development | $316.90M | $221.63M | $189.15M | $184.50M | $116.43M | $66.49M | $45.02M | $40.51M |
| Operating income | -$285.67M | -$213.03M | -$155.06M | -$183.87M | -$117.89M | -$64.98M | -$22.24M | -$9.74M |
| Net income | -$264.46M | -$193.57M | -$143.95M | -$180.36M | -$117.19M | -$43.24M | -$21.70M | -$9.43M |
| EBITDA | -$277.13M | -$207.89M | -$146.83M | -$172.63M | -$110.10M | -$62.53M | -$19.99M | -$6.75M |
Quarterly
| Line item | Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $673.06M | $9.04M | $6.25M | $13.58M | $7.89M | $44.06M | $18.45M | $13.28M | $12.59M | $12.09M | $16.59M | $15.16M |
| Gross profit | $673.06M | $9.04M | $6.25M | $13.58M | $7.89M | $44.06M | $18.45M | $13.28M | $12.59M | $12.09M | $16.59M | $15.16M |
| Operating income | $559.45M | -$94.20M | -$92.50M | -$83.09M | -$91.39M | -$48.32M | -$62.86M | -$64.66M | -$54.61M | -$48.54M | -$45.22M | -$45.33M |
| Net income | $549.81M | -$89.53M | -$87.17M | -$78.22M | -$86.42M | -$43.46M | -$56.35M | -$58.55M | -$48.96M | -$44.55M | -$41.52M | -$41.96M |
Balance Sheet
As of Nov 2025, cash and equivalents exceeded short-term debt of $2.82M by $244.14M.
Annual
| Line item | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 | Nov 2020 | Nov 2019 | Nov 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $688.13M | $669.34M | $355.60M | $416.76M | $476.77M | $396.34M | $44.05M | $45.40M |
| Current assets | $606.82M | $619.39M | $295.50M | $318.45M | $311.12M | $298.43M | $39.35M | $40.65M |
| Cash and equivalents | $246.96M | $110.00M | $54.63M | $64.47M | $80.51M | $119.36M | $34.82M | $25.59M |
| Total liabilities | $149.39M | $142.35M | $155.10M | $113.06M | $134.47M | $106.07M | $53.57M | $34.05M |
| Short-term debt | $2.82M | $8.01M | $7.49M | $5.53M | $3.85M | $7.63M | $4.62M | $2.84M |
| Shareholder equity | $538.75M | $526.99M | $200.49M | $303.70M | $342.30M | $290.27M | -$57.71M | -$36.85M |
Quarterly
| Line item | Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.20B | $535.54M | $636.13M | $688.13M | $522.47M | $591.55M | $615.04M | $669.34M | $513.60M | $511.03M | $312.67M | $355.60M |
| Total liabilities | $226.99M | $132.91M | $155.24M | $149.39M | $150.22M | $143.95M | $134.13M | $142.35M | $136.74M | $140.34M | $143.93M | $155.10M |
| Cash and equivalents | $720.24M | $67.69M | $71.19M | $246.96M | $78.44M | $84.26M | $75.92M | $110.00M | $99.04M | $116.79M | $49.81M | $54.63M |
| Shareholder equity | $968.31M | $402.63M | $480.89M | $538.75M | $372.25M | $447.60M | $480.92M | $526.99M | $376.86M | $370.69M | $168.75M | $200.49M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Nov 2025.
Annual
| Line item | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 | Nov 2020 | Nov 2019 | Nov 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$249.47M | -$172.58M | -$81.36M | -$159.81M | -$84.36M | -$80.00K | $601.00K | -$31.68M |
| Capital expenditures | $14.00M | $9.27M | $8.40M | $12.24M | $5.66M | $4.55M | $1.65M | $1.59M |
| Free cash flow | -$263.47M | -$181.86M | -$89.77M | -$172.05M | -$90.03M | -$4.63M | -$1.05M | -$33.27M |
| Investing cash flow | $147.85M | -$257.71M | $68.30M | $27.20M | -$108.25M | -$254.40M | $8.50M | $39.99M |
| Financing cash flow | $238.64M | $485.67M | $3.22M | $117.19M | $153.88M | $339.02M | $126.00K | $529.00K |
Quarterly
| Line item | Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $615.63M | -$96.57M | -$71.91M | -$67.83M | -$57.38M | -$63.16M | -$61.09M | -$48.75M | -$42.18M | -$39.70M | -$41.95M | $26.69M |
| Capital expenditures | $1.39M | $1.94M | $1.04M | $5.13M | $2.71M | $2.67M | $3.48M | $2.10M | $2.35M | $1.94M | $2.88M | $2.58M |
| Free cash flow | $614.24M | -$98.51M | -$72.96M | -$72.96M | -$60.10M | -$65.84M | -$64.57M | -$50.86M | -$44.52M | -$41.64M | -$44.84M | $24.10M |
Frequently Asked Questions About NRIX
What is Nurix Therapeutics' annual revenue?
Nurix Therapeutics reported revenue of $83.98M for the fiscal year ended Nov 30, 2025.
How fast is Nurix Therapeutics' revenue growing?
Revenue was up 54.0% for the fiscal year ended Nov 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 29.5%.
Is Nurix Therapeutics profitable?
No. Nurix Therapeutics reported net income of -$264.46M for the fiscal year ended Nov 30, 2025, with a net margin of -314.9%.
How much free cash flow does NRIX generate?
For the fiscal year ended Nov 30, 2025, operating cash flow of -$249.47M minus capital expenditures of $14.00M produced free cash flow of -$263.47M.
How much debt does Nurix Therapeutics have?
The balance sheet dated Nov 30, 2025 reported short-term debt of $2.82M and cash and equivalents of $246.96M.
NRIX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors